Status:

UNKNOWN

Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis

Lead Sponsor:

Flemming Bendtsen

Conditions:

Ulcerative Colitis

Eligibility:

All Genders

18-60 years

Phase:

PHASE4

Brief Summary

Several oral mesalazine (5-ASA) formulations exist, but the regimes require several tablets per day. Such regimens are not ideal and can interfere with normal daily activities of patients. Non-adheren...

Eligibility Criteria

Inclusion

  • Signed informed consent
  • Age between and including 18 and 60
  • Diagnosed with UC according to the Copenhagen Diagnostic Criteria
  • Length of disease of max. 10 years
  • Stable remission on 5-ASA (defined as partial Mayo score ≤1) for at least 2 months without need for oral corticosteroids before inclusion.
  • Endoscopic remission defined as Mayo Clinic Endoscopic Score \< 2
  • Have had a relapse within the last 2 years
  • Defined as the need of escalation of treatment or change medical treatment.

Exclusion

  • Evidence of infectious diarrhoea (i.e. pathogenic viruses, bacteria or Clostridium difficile toxin in stool culture) within the last month
  • On immunomodulators, including methotrexate
  • On any biological therapy
  • Any previous abdominal surgery related to UC
  • Any chronic infections (e.g. HBV, HCV, HIV)
  • Any severe concomitant cardiovascular, autoimmune, hematologic, hepatic, renal, endocrine, oncologic or psychiatric disorder, which in the opinion of the investigator might have an influence on the patient's compliance or the interpretation of the results
  • Well-founded doubt about the patient's cooperation, e.g., because of addiction to alcohol or drugs in the opinion of the investigators.
  • Participation in another clinical trial within the last 30 days, or simultaneous participation in another clinical trial.
  • Any previous documented allergic reaction to tested the medical drugs

Key Trial Info

Start Date :

November 28 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

March 1 2025

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT04133194

Start Date

November 28 2019

End Date

March 1 2025

Last Update

September 26 2023

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Copenhagen University Hospital Hvidovre

Hvidovre, Denmark, 2200